Search icon

ENVISION HEALTH TECHNOLOGIES INC

Company claim

Is this your business?

Get access!

Company Details

Name: ENVISION HEALTH TECHNOLOGIES INC
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 21 Mar 2023 (2 years ago)
Entity Number: 6771735
ZIP code: 11226
County: Westchester
Place of Formation: Delaware
Foreign Legal Name: ENVISION HEALTH TECHNOLOGIES INC
Address: 760 Parkside Avenue Suite 227D, Brooklyn, NY, United States, 11226

DOS Process Agent

Name Role Address
ENVISION HEALTH TECHNOLOGIES INC DOS Process Agent 760 Parkside Avenue Suite 227D, Brooklyn, NY, United States, 11226

Chief Executive Officer

Name Role Address
LAMA A. AL-ASWAD, MD, MPH Chief Executive Officer 760 PARKSIDE AVENUE SUITE 227D, BROOKLYN, NY, United States, 11226

History

Start date End date Type Value
2023-03-22 2025-03-05 Address 16 sturgis rd, BRONXVILLE, NY, 10708, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
250305002445 2025-03-05 BIENNIAL STATEMENT 2025-03-05
230322002450 2023-03-21 APPLICATION OF AUTHORITY 2023-03-21

USAspending Awards / Financial Assistance

Date:
2024-07-24
Awarding Agency Name:
National Science Foundation
Transaction Description:
SBIR PHASE I: ADAPTIVE PERIMETRY FOR HEAD MOUNTED DEVICES -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS THE DEVELOPMENT OF A NOVEL TOOL FOR THE DIAGNOSIS AND MONITORING OF FUNCTIONAL VISUAL FIELD (VF) DEFECTS DUE TO GLAUCOMA.?GLAUCOMA, A LEADING CAUSE OF BLINDNESS, IS ASYMPTOMATIC IN ITS EARLY STAGES AND CHALLENGING TO DIAGNOSE, OFTEN RESULTING IN LATE DETECTION.?3 MILLION AMERICANS HAVE A DIAGNOSIS OF GLAUCOMA, AND THIS NUMBER IS EXPECTED TO DOUBLE BY 2050 CONTRIBUTING TO A MARKET SIZE FOR TREATMENT EXCEEDING $7 BILLION BY 2028. EARLY IDENTIFICATION OF DISEASE AND DISEASE PROGRESSION IS KEY IN PREVENTING VISION LOSS. USING A NOVEL TESTING METHOD, THIS TECHNOLOGY WILL CAPTURE VF CHANGES WITH HIGHER SENSITIVITY AND SPECIFICITY THAN THE CURRENT STANDARD OF CARE. IF SUCCESSFUL, THE PROPOSED SOLUTION WILL ALLOW FOR EARLIER DETECTION OF GLAUCOMA AND GLAUCOMATOUS PROGRESSION AND FACILITATE EARLIER CLINICAL INTERVENTION BY EYE CARE PROVIDERS, REDUCING THE OVERALL BURDEN OF DISEASE AND INCIDENCE OF IRREVERSIBLE VISION LOSS.??? ?? THIS SMALL BUSINESS INNOVATION RESEARCH PHASE I PROJECT AIMS?TO IMPROVE THE EARLY DETECTION OF VISION LOSS DUE TO GLAUCOMA THROUGH THE DEVELOPMENT OF FULLY AUTOMATED ADAPTIVE PERIMETRY SOFTWARE. CONVENTIONAL VF TESTING, KNOWN AS STATIC AUTOMATED PERIMETRY (SAP), LACKS SENSITIVITY, OFTEN LEADING TO LATE DIAGNOSIS OF GLAUCOMA AND IRREVERSIBLE VISION LOSS. WITH SAP, DEFECTS CAN ONLY BE DETECTED WHEN THEY AFFECT AT LEAST 3 DEGREES OF THE VISUAL FIELD, PROVIDING ONLY A MACRO UNDERSTANDING OF VISION LOSS. THIS PROJECT AIMS TO DEVELOP A FULLY AUTOMATED ADAPTIVE PERIMETRY TEST THAT COMBINES THE UNIFORMITY AND STANDARDIZATION OF SAP WITH GREATER PRECISION AND INDIVIDUALIZATION OF AN ADAPTIVE TEST STRATEGY. THIS NOVEL TESTING ALGORITHM WILL INTELLIGENTLY ADJUST STIMULI BASED ON INDIVIDUAL RESPONSES, INCREASING THE SENSITIVITY AND SPECIFICITY OF EARLY DEFECT DETECTION, AND MAPPING FUNCTIONAL DEFICITS TO RETINAL ANATOMICAL DEFECTS. OBJECTIVES INCLUDE MATHEMATICAL MODELING OF THE RETINAL PATHOPHYSIOLOGY OF GLAUCOMA, DEVELOPMENT OF SPATIAL ANALYSIS FOR REAL-TIME TEST LOCATION DETERMINATION, DEVELOPMENT OF METHODS FOR ACTIVE CORRECTION OF FIXATIONAL ERRORS USING EYE-TRACKING, AND DETERMINATION OF SUPRATHRESHOLD CONTRASTS.? THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.
Obligated Amount:
275000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
97804684
Mark:
GAMIFEYES
Status:
SECOND EXTENSION - GRANTED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2023-02-21
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
GAMIFEYES

Goods And Services

For:
Downloadable medical software for eye health diagnostics, predictions and therapeutics; Downloadable computer software for eye health diagnostics, predictions and therapeutics; Downloadable computer game software for eye health diagnostics, predictions and therapeutics; recorded software for eye hea...
International Classes:
009 - Primary Class
Class Status:
Active
For:
Providing online, non-downloadable software applications for eye health diagnostics, predictions and therapeutics; online non-downloadable eye health software for eye health diagnostics, predictions and therapeutics; online non-downloadable software featuring games for eye health diagnostics, predic...
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
97804642
Mark:
ENVISION HEALTH TECHNOLOGIES
Status:
SECOND EXTENSION - GRANTED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2023-02-21
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
ENVISION HEALTH TECHNOLOGIES

Goods And Services

For:
Downloadable medical software for eye health diagnostics, predictions and therapeutics; Downloadable computer software for eye health diagnostics, predictions and therapeutics; Downloadable computer game software for eye health diagnostics, predictions and therapeutics; recorded software for eye hea...
International Classes:
009 - Primary Class
Class Status:
Active
For:
Providing online, non-downloadable software applications for eye health diagnostics, predictions and therapeutics; online non-downloadable eye health software for eye health diagnostics, predictions and therapeutics; online non-downloadable software featuring games for eye health diagnostics, predic...
International Classes:
042 - Primary Class
Class Status:
Active

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 20 Mar 2025

Sources: New York Secretary of State